-
公开(公告)号:US20220033392A1
公开(公告)日:2022-02-03
申请号:US17226531
申请日:2021-04-09
发明人: Nicholas E. Bencivenga , David C. Dalgarno , Joseph M. Gozgit , Wei-Sheng Huang , Anna Kohlmann , Feng Li , Jiwei Qi , William C. Shakespeare , Ranny M. Thomas , Yihan Wang , Xiaotian Zhu
IPC分类号: C07D417/12 , C07D417/04 , C07D277/46
摘要: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: wherein A, L, R1, R2, R3, and n are described herein.
-
公开(公告)号:US20210323976A1
公开(公告)日:2021-10-21
申请号:US15573211
申请日:2016-05-12
发明人: Wei-Sheng Huang , Tianjun Zhou , Willmen W. Youngsaye , William C. Shakespeare , Alexey V. Ishchenko , David C. Dalgarno
IPC分类号: C07D498/04 , C07D487/04 , C07D471/04 , C07D491/147 , C07D403/04
摘要: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFRand mutant HER2 activity, are described herein.
-
公开(公告)号:US20200231588A1
公开(公告)日:2020-07-23
申请号:US16722881
申请日:2019-12-20
发明人: Dong Zou , Wei-Sheng Huang , R. Mathew Thomas , Jan Antoinette C. Romero , Jiwei Qi , Yihan Wang , Xiaotian Zhu , William C. Shakespeare , Rajeswari Sundaramoorthi , Chester A. Metcalf, III , David C. Dalgarno , Tomi K. Sawyer
IPC分类号: C07D471/04 , C07D473/34 , C07D487/04
摘要: This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
-
公开(公告)号:US20170253594A1
公开(公告)日:2017-09-07
申请号:US15600023
申请日:2017-05-19
发明人: Wei-Sheng Huang , Yongjin Gong , Feng Li , Nicholas E. Bencivenga , David C. Delgamo , Anna Kohlmann , William C. Shakespeare , Ranny M. Thomas , Xiaotian Zhu , Angela V. West , Willmen Youngsaye , Yun Zhang , Tianjun Zhou
IPC分类号: C07D471/04 , C07D403/04 , C07D401/14 , C07D405/12 , C07F9/6558
CPC分类号: C07D471/04 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/12 , C07D405/14 , C07F9/65583
摘要: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
-
公开(公告)号:US20130231337A1
公开(公告)日:2013-09-05
申请号:US13801116
申请日:2013-03-13
发明人: Dong Zou , Wei-Sheng Huang , R. Mathew Thomas , Jan Antoinette C. Romero , Jiwei Qi , Yihan Wang , Xiaotian Zhu , William C. Shakespeare , Rajeswari Sundaramoorthi , Chester A. Metcalf, III , David C. Dalgarno , Tomi K. Sawyer
IPC分类号: C07D487/04 , C07D473/34 , C07D471/04
CPC分类号: C07D471/04 , C07D473/34 , C07D487/04
摘要: This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
摘要翻译: 本发明涉及以下通式的化合物:其中可变基团如本文所定义,及其制备和用途。
-
公开(公告)号:US11180482B2
公开(公告)日:2021-11-23
申请号:US16465073
申请日:2017-11-29
发明人: Wei-Sheng Huang , Yun Zhang , Willmen Youngsaye , Xiaotian Zhu , Erin Geno
IPC分类号: C07D403/12 , C07D403/14 , C07D239/48 , C07D401/12 , C07D405/14 , C07D455/04
摘要: The invention relates to HPK1 inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: where A, R1, R2, R3, R4, R5, R6, R16, R17, X1, X2, X3, X4, m, and n are described herein.
-
公开(公告)号:US11117883B2
公开(公告)日:2021-09-14
申请号:US16469535
申请日:2017-12-14
发明人: Nicholas E. Bencivenga , David C. Dalgarno , Joseph M. Gozgit , Wei-Sheng Huang , Anna Kohlmann , Feng Li , Jiwei Qi , William C. Shakespeare , Ranny M. Thomas , Yihan Wang , Yun Zhang , Xiaotian Zhu
IPC分类号: A61K31/4184 , A61K31/4178 , A61K31/4439 , A61K31/4427 , C07D403/14 , C07D403/12 , C07D403/04 , C07D401/14 , C07D401/12 , C07D413/14 , C07D405/14
摘要: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: (I) where A, L, R1, R2, R3, and n are described herein.
-
公开(公告)号:US11001580B2
公开(公告)日:2021-05-11
申请号:US16469517
申请日:2017-12-14
发明人: Nicholas E. Bencivenga , David C. Dalgarno , Joseph M. Gozgit , Wei-Sheng Huang , Anna Kohlmann , Feng Li , Jiwei Qi , William C. Shakespeare , Ranny M. Thomas , Yihan Wang , Xiaotian Zhu
IPC分类号: C07D417/14 , C07D417/12
摘要: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other-threonine kinase mediated diseases, having the Formula: (I) wherein A, L, R1, R2, R3, and n are described herein.
-
公开(公告)号:US20190218212A1
公开(公告)日:2019-07-18
申请号:US16257577
申请日:2019-01-25
发明人: Wei-Sheng Huang , Yongjin Gong , Feng Li , Nicholas E. Bencivenga , David C. Dalgarno , Anna Kohlmann , William C. Shakespeare , Ranny M. Thomas , Xiaotian Zhu , Angela V. West , Willmen Youngsaye , Yun Zhang , Tianjun Zhou
IPC分类号: C07D471/04 , C07F9/6558 , C07D405/12 , C07D403/04 , C07D403/14 , C07D405/14 , C07D401/14 , C07D401/04
CPC分类号: C07D471/04 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/12 , C07D405/14 , C07F9/65583
摘要: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
-
公开(公告)号:US20190031656A1
公开(公告)日:2019-01-31
申请号:US16055362
申请日:2018-08-06
发明人: Dong Zou , Wei-Sheng Huang , R. Mathew Thomas , Jan Antoinette C. Romero , Jiwei Qi , Yihan Wang , Xiaotian Zhu , William C. Shakespeare , Rajeswari Sundaramoorthi , Chester A. Metcalf, III , David C. Dalgarno , Tomi K. Sawyer
IPC分类号: C07D471/04 , C07D473/34 , C07D487/04
摘要: This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
-
-
-
-
-
-
-
-
-